Literature DB >> 14597644

Effect of blood pressure on early decline in kidney function among hypertensive men.

Suma Vupputuri1, Vecihi Batuman, Paul Muntner, Lydia A Bazzano, John J Lefante, Paul K Whelton, Jiang He.   

Abstract

Few cohort studies have examined the longitudinal association between change in blood pressure and decline in kidney function among treated hypertensive patients without chronic kidney disease. We conducted a nonconcurrent cohort study to examine the effects of blood pressure on estimated glomerular filtration rate and early kidney function decline (rise in serum creatinine > or =0.6 mg/dL during follow-up) among 504 African-American and 218 white hypertensive patients. Our results showed that each standard deviation higher treated systolic (18 mm Hg) and diastolic (10 mm Hg) blood pressure was associated with an average annual decline (95% confidence interval [CI]) in estimated glomerular filtration rate of -0.92 ([-1.49 to -0.36] P=0.001) and -0.83 ([-1.38 to -0.28] P=0.003) mL x min(-1) x 1.73 m(-2), respectively, after adjustment for race, age, education, income, use of antihypertensive drugs, body mass index, and history of diabetes and dyslipidemia. Likewise, each standard deviation higher systolic and diastolic blood pressure was associated with relative risks (95% CIs) of 1.81 ([1.29 to 2.55] P<0.001) and 1.55 ([1.08 to 2.22] P=0.046), respectively, for early kidney function decline. Compared with patients with a blood pressure level <140/90 mm Hg, those with a blood pressure level > or =160/95 mm Hg had a -2.67 ([-4.01 to -1.32] P<0.001) mL x min(-1) x 1.73 m(-2) greater annual decline in estimated glomerular filtration rate and a 5.21-fold ([2.06 to 13.21] P<0.001) greater risk of early kidney function decline. Our study found that higher levels of treated blood pressure were positively and significantly related to early decline in kidney function among hypertensive men. These results indicate that better blood pressure control might prevent the onset of chronic kidney disease among hypertensives.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14597644     DOI: 10.1161/01.HYP.0000101695.56635.31

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  28 in total

1.  Effects of developmental lead exposure on the hippocampal transcriptome: influences of sex, developmental period, and lead exposure level.

Authors:  Jay S Schneider; David W Anderson; Keyur Talsania; William Mettil; Rajanikanth Vadigepalli
Journal:  Toxicol Sci       Date:  2012-05-28       Impact factor: 4.849

Review 2.  Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease.

Authors:  Rikki M Tanner; Todd M Brown; Paul Muntner
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

3.  A chromosome 11q quantitative-trait locus influences change of blood-pressure measurements over time in Mexican Americans of the San Antonio Family Heart Study.

Authors:  Sue Rutherford; Guowen Cai; Juan C Lopez-Alvarenga; Jack W Kent; V Saroja Voruganti; J Michael Proffitt; Joanne E Curran; Mathew P Johnson; Thomas D Dyer; Jeremy B Jowett; Raul A Bastarrachea; Larry D Atwood; Harald H H Goring; Jean W Maccluer; Eric K Moses; John Blangero; Anthony G Comuzzie; Shelley A Cole
Journal:  Am J Hum Genet       Date:  2007-08-20       Impact factor: 11.025

Review 4.  The fourth-generation Calcium channel blocker: cilnidipine.

Authors:  K Sarat Chandra; G Ramesh
Journal:  Indian Heart J       Date:  2013-12

5.  Clinicians' guide to statistics for medical practice and research: part I.

Authors:  Marie A Krousel-Wood; Richard B Chambers; Paul Muntner
Journal:  Ochsner J       Date:  2006

6.  Racial and ethnic differences in kidney function decline among persons without chronic kidney disease.

Authors:  Carmen A Peralta; Ronit Katz; Ian DeBoer; Joachim Ix; Mark Sarnak; Holly Kramer; David Siscovick; Steven Shea; Moyses Szklo; Michael Shlipak
Journal:  J Am Soc Nephrol       Date:  2011-06-23       Impact factor: 10.121

7.  Kidney disease and the cumulative burden of life course socioeconomic conditions: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  David A Shoham; Suma Vupputuri; Jay S Kaufman; Abhijit V Kshirsagar; Ana V Diez Roux; Josef Coresh; Gerardo Heiss
Journal:  Soc Sci Med       Date:  2008-07-28       Impact factor: 4.634

8.  Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).

Authors:  Takashi Wada; Tatsuo Hosoya; Daisuke Honda; Ryusuke Sakamoto; Kazutaka Narita; Tomomitsu Sasaki; Daisuke Okui; Kenjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2018-01-25       Impact factor: 2.801

9.  End-stage renal disease in young black males in a black-white population: longitudinal analysis of the Bogalusa Heart Study.

Authors:  Paul Muntner; Asghar Arshad; Stephen A Morse; Dharmendrakumar A Patel; Pronabesh D Manapatra; Efrain Reisin; Erwin A Aguilar; Wei Chen; Sathanur Srinivasan; Gerald S Berenson
Journal:  BMC Nephrol       Date:  2009-12-02       Impact factor: 2.388

10.  Incident chronic kidney disease and the rate of kidney function decline in individuals with hypertension.

Authors:  Rebecca Hanratty; Michel Chonchol; L Miriam Dickinson; Brenda L Beaty; Raymond O Estacio; Thomas D Mackenzie; Laura P Hurley; Stuart L Linas; John F Steiner; Edward P Havranek
Journal:  Nephrol Dial Transplant       Date:  2009-11-04       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.